FY2026 Earnings Estimate for BDRX Issued By Zacks Research

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) – Investment analysts at Zacks Research issued their FY2026 earnings per share (EPS) estimates for shares of Biodexa Pharmaceuticals in a report issued on Monday, March 30th. Zacks Research analyst D. Bautz expects that the company will post earnings of $0.00 per share for the year. The consensus estimate for Biodexa Pharmaceuticals’ current full-year earnings is ($1.25) per share. Zacks Research also issued estimates for Biodexa Pharmaceuticals’ FY2027 earnings at $0.00 EPS.

Biodexa Pharmaceuticals (NASDAQ:BDRX) last released its earnings results on Friday, March 27th. The company reported $0.70 EPS for the quarter.

A number of other equities research analysts have also recently commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a report on Monday, December 29th. Wall Street Zen lowered shares of Biodexa Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Biodexa Pharmaceuticals presently has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Price Performance

Shares of BDRX opened at $0.61 on Wednesday. Biodexa Pharmaceuticals has a 52-week low of $0.60 and a 52-week high of $19.30. The business’s 50 day moving average price is $1.15 and its two-hundred day moving average price is $3.79.

Shares of Biodexa Pharmaceuticals are scheduled to reverse split on Monday, April 6th. The 1-5 reverse split was announced on Wednesday, March 18th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, April 3rd.

Hedge Funds Weigh In On Biodexa Pharmaceuticals

A hedge fund recently bought a new stake in Biodexa Pharmaceuticals stock. Armistice Capital LLC bought a new position in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned approximately 14.71% of Biodexa Pharmaceuticals as of its most recent SEC filing. 17.51% of the stock is currently owned by institutional investors and hedge funds.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.